US2293359A - Acetyl salicylic acid preparation - Google Patents
Acetyl salicylic acid preparation Download PDFInfo
- Publication number
- US2293359A US2293359A US373611A US37361141A US2293359A US 2293359 A US2293359 A US 2293359A US 373611 A US373611 A US 373611A US 37361141 A US37361141 A US 37361141A US 2293359 A US2293359 A US 2293359A
- Authority
- US
- United States
- Prior art keywords
- salicylic acid
- acetyl salicylic
- interspersing
- preparations
- acetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title description 68
- 229960001138 acetylsalicylic acid Drugs 0.000 title description 66
- 238000002360 preparation method Methods 0.000 title description 55
- 239000003795 chemical substances by application Substances 0.000 description 52
- 239000002245 particle Substances 0.000 description 48
- 239000003826 tablet Substances 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 238000000034 method Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 239000000463 material Substances 0.000 description 16
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 13
- 230000002070 germicidal effect Effects 0.000 description 13
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 12
- 229950011008 tetrachloroethylene Drugs 0.000 description 12
- 230000005484 gravity Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 239000001506 calcium phosphate Substances 0.000 description 7
- 238000003801 milling Methods 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 7
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229940078499 tricalcium phosphate Drugs 0.000 description 6
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 6
- 235000019731 tricalcium phosphate Nutrition 0.000 description 6
- 239000005995 Aluminium silicate Substances 0.000 description 5
- 239000004965 Silica aerogel Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 235000012211 aluminium silicate Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229960004889 salicylic acid Drugs 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 4
- 239000011295 pitch Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000395 magnesium oxide Substances 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000195947 Lycopodium Species 0.000 description 2
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- AVYUKZRROFQFPA-UHFFFAOYSA-N Strychnin Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OC=CC2CN2C1C46CC2 AVYUKZRROFQFPA-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- -1 antimony chloride Chemical class 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000010410 dusting Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 229960005453 strychnine Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical compound [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 1
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
- GNYWBJRDQHPSJL-UHFFFAOYSA-N 6-acetyl-6-hydroxycyclohexa-2,4-diene-1-carboxylic acid Chemical compound CC(=O)C1(O)C=CC=CC1C(O)=O GNYWBJRDQHPSJL-UHFFFAOYSA-N 0.000 description 1
- 241001385464 Acidon Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100025840 Coiled-coil domain-containing protein 86 Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000932708 Homo sapiens Coiled-coil domain-containing protein 86 Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical class C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- FAPDDOBMIUGHIN-UHFFFAOYSA-K antimony trichloride Chemical compound Cl[Sb](Cl)Cl FAPDDOBMIUGHIN-UHFFFAOYSA-K 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000010426 asphalt Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide Chemical compound [S-2].[Cu+2] OMZSGWSJDCOLKM-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001235 gentian violet Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- PIJPYDMVFNTHIP-UHFFFAOYSA-L lead sulfate Chemical compound [PbH4+2].[O-]S([O-])(=O)=O PIJPYDMVFNTHIP-UHFFFAOYSA-L 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 1
- KBGKQZVCLWKUDQ-UHFFFAOYSA-N luteolin-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)C=C(C=1C=C(O)C(O)=CC=1)O2 KBGKQZVCLWKUDQ-UHFFFAOYSA-N 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000320 mechanical mixture Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- WRWRKDRWMURIBI-UHFFFAOYSA-M mercuric amidochloride Chemical compound N[Hg]Cl WRWRKDRWMURIBI-UHFFFAOYSA-M 0.000 description 1
- 229960000432 mercuric amidochloride Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000011301 petroleum pitch Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 150000003870 salicylic acids Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940096017 silver fluoride Drugs 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- REYHXKZHIMGNSE-UHFFFAOYSA-M silver monofluoride Chemical compound [F-].[Ag+] REYHXKZHIMGNSE-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JZLOKWGVGHYBKD-UHFFFAOYSA-M sodium;2-acetyloxybenzoate Chemical compound [Na+].CC(=O)OC1=CC=CC=C1C([O-])=O JZLOKWGVGHYBKD-UHFFFAOYSA-M 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Definitions
- My invention relates to preparations of acetyl salicylic acid, having new and unpredictable physical, germicidal, and pharmacological properties. and having a particle size far smaller than has been known heretofore in preparations of acetyl salicylic acid.
- Another object is to provide acetyl salicylic acid of increased therapeutic eilicacy.
- Another object is to provide tablets, dusting powder, chewing gum, confections, or lozenges, containing acetyl salicylic acid in a state of increased availability to living organisms.
- Another object is to provide tablets of acetyl salicylic acid, which will dissolve more rapidly and be more efficacious as an antiseptic or analgesic than products containing acetyl salicylic in like amount prior to this invention.
- I have prepared comminuted acetyl salicylic acid, having an average diameter of the particles substantially less than 14 microns, preferably less than nine microns and in the order of two to eight microns, and even less than two microns.
- Suitable anti-electrostatic and/or interspersing agents include any inorganic or organic substances, or combinations thereof, which are millable, whereby I mean those that are sumciently hard and brittle to be millable without caking in a mill. such as a ball mill, hammer mill, or the like, or which are otherwise available in an extremely fine state of comminution.
- interspersing agents are for example almost allinorganic salts, or minerals, with a few exceptions readily discernible and obvious to those skilled in the art. These examples are primarily the highly hygroscopic salts, such as lithium bromide or silver fluoride, which may be used under anhydrous conditions, but are not desirable for practical purposes; the exceptionally soft salts, such as antimony chloride, which can not be readily milled because of their softness: and substances which are incompatible with acetyl salicylic acid, reacting with this acid to form unstable compounds, such as sodium carbonate, sodium bicarbonate, magnesium oxide, calcium oxide, or hydroxide, and the like.
- highly hygroscopic salts such as lithium bromide or silver fluoride
- antimony chloride which can not be readily milled because of their softness
- interspersing agent to mean a substance, which under the test conditions described above will delay the caking of acetyl salicylic acid substantially beyond the time reouired to comminute it to an average particle ing agents, to avoid substances likely not to give good results, and the above testing procedure will merely serve as a supplemental aid in the selection, and for definition of substances suitable as interspersing agents.
- interspersing agents may be mentioned particularly tri-calcium phosphate, and silica aerogel, prepared as disclosed in the U. S. P. 2,093,454, issued September 21, 1937, to S. S. Kistler. It was found that the admixture of only .2% to .9% of either of these substances, and/or 1% to 2% boric acid fully prevented caking of acetyl salicylic acid, even on milling in. a pebble mill for eight hours or more, or to an average particle size of 2 microns, or less. The finest particle sizes were generally attained using slightly larger amounts, say
- interspersing agents Kaolin was also very suitable, but should preferably be used in amounts of about 7 to 15% by weight.
- suitable interspersing agents were inorganic solids substantially chemically inert to acetyl salicylic acid, such as kaolin, magnesium silicate, carbon, sulphur, calcium phosphates, ferric acetate, boric acid, silver chloride, lead sulphate, barium sulphate, lead bichromate, copper sulfide, mercuric ammonium chloride, aluminum powder and the like.
- the suitable materials were found among those having a relatively high degree of hardness and brittleness, at the temperature of the comminution process, or otherwise available in an unusually fine degree of comminution, such as for example strychnin,
- ephetirin sulphate ephetirin sulphate, galuteolin, lycopodium spores, and the hard black resinous composite materials remaining in the still upon distilling off all material as volatile at 300 degrees C. in 1 mm. vacuum from a petroleum pitch, and the like.
- Example 1 99.7 parts by weight of crystalline acetyl salicylic acid were thoroughly intermixed with .3 part by weight of finely powdered tri-calcium phosphate, and milled in a ball mill with pebbles, at 70 revolutions per minute. After four hours the milling was interrupted, and the comminuted product removed. It was found to have an average particle size of 6 microns. The apparent specific gravity was .682, or approximately lower than the apparent specific gravities of the finest powdered acetyl salicylic acid preparations hitherto available.
- the preparations contemplated in this invention unless subjected to compression or like treatments, subsequently to their preparation, have apparent specific gravities below .880, while the most finely comminuted acetyl salicylic acid preparations known heretofore have apparent specific gravities appreciably higher than .880,
- the preparation offered very little resistance to solid objects; even a relatively light object such as a piece of wood fell through even a foot deep layer of the milled product, while of course such a piece of light material would not at all sink through the finest acetyl salicylic acid previously known.
- the product of this invention behaved almost like a liquid, or like colloidal carbon: it flowed when handled in a glass container, always forming a substantially horizontal surface, and, on agitation with a glass rod or a pencil. it offered hardly any percepticle resistance. Viewed under the microscope; in the dark field of a cardioid condenser, suspended in a non-solvent liquid medium such as a concentrated solution of acetyl salicylicacid in an oil, or in perchlorethylene, it showed a large number of extremely minute particles, smaller than .1 micron, and having vivid Brownian motion.
- a non-solvent liquid medium such as a concentrated solution of acetyl salicylicacid in an oil, or in perchlorethylene
- the resin thus purified was very brittle, and was completely soluble in perchlorethylene.
- This resin was comminuted as finely as possible with mortar and pestle, and was then intermixed with twice its weight of acetyl salicylic acid, and the mixture was placed in a pebble mill.
- the mill jar was immersed in a cooling bath consisting of acetone saturated with solid carbon dioxide. Additional solid carbon dioxide was added from time to time, so that some undissolved carbon dioxide was present throughout the experiment in sufilcient amounts to maintain a uniform very low temperature, but not in such quantities as to interfere with the operation of the pebble mill. The mill was not started until after an hour of cooling to allow time for uniform temperature throughout the charge.
- the mill was then operated two hours.
- the resultant powder had an average particle size of 6 microns.
- This powder was intermixed with an excess of perchlorethylene, which dissolved the resin, but did not dissolve acetyl salicylic acid to any appreciable extent, particularly if the perchlorethylene had been kept in contact with acetyl salicylic acid prior to its use in this process.
- the acetyl salicylic acid was separated from the resin solution by centrifugation, and was washed from traces of the resin containing solution by repeated suspension in benzene, and centrifugation. It was freed from excess liquid by centrifugation and rapid drying.
- the resultant acetyl salicylic acid had an average particle size of six microns, and wasfree from the interspersing agent.
- classification it was possible to separate this preparation in fractions of different fineness. This could be done, for example, by allowing a vertical air current to pass upwardly through the preparation, and by collecting the particles carried upward on a dust filter made of cotton in the upper part of the tube, in manner obvious cardioid condenser, to have a particle size well below one micron.
- acetyl salicylic acid prepared directly by milling with an interspersing agent obviously can be separated into fractions of different particle size by the methods already outlined.
- Industrially, the most practical method is that of separation of the finer particles by air current, in a cyclon" type separated, well known in the art. In this manner preparations having an average particle size as low as .1 micron, and less, were found to be obtainable.
- any other liquid which is substantially a nonsolvent for acetyl salicylic acid, and a solvent for the interspersing agent employed is suitable, such as for example benzene and carbon-tetrachloride.
- interspersing agent a mixture of equal parts of Petrex" and Santo resin" with three times their combined weight of acetyl salicylic acid, the comminution was carried out sucessfully in a ball mill at room temperature, and both carbon-tetrachloride and benzene, respectively. were used to separate the interspersing agent from the acetyl salicylic acid.
- the pure finely comminuted acetyl salicylic acid preparations thus prepared obviously may be compounded with other ingredients used in medicine, and may be compressed into tablets.
- interspersing agents are so great, and their properties so varied, that it is easy to find one suitable for almost any requirement.
- a composition comprising less than 5% of a therapeutically inert interspersing. agent, such as kaolin, or say .2% to 3% of tricalcium phosphate, and/or silica aerogel can be used freely in therapeutical compositions, the amount of these interspersing agents present being therapeutically negligible.
- the finely comminuted acetyl salicylic acid preparations described above are eminently adapted for use as dusting powders for example for local treatment to infiammations of mucous membranes of the human body.
- the extreme ease of distribution of this powder by blowing or spraying, as well as the surprising antiseptic properties described below render them far superior to acetyl salicylic acid preparations previously available for these purposes, and particularly superior to the preparation contemplated in the British patent to Sefton-Jones, 25,486 (1912), which is chemically unstable and practically devoid of antiseptic properties, as will be described later in this specification.
- the preparations of pure acetyl salicylic acid of an average particle size substantially below 14 microns, as well as the preparations in which the interspersing agents are present, are for most purposes conveniently used in the form of tablets.
- the preparations are intermixed with a tablet disintegrating agent having the property of swelling, so as to break up the tablets when in contact with aqueous fluids, such as for example, water, or gastric juice.
- a tablet disintegrating agent having the property of swelling, so as to break up the tablets when in contact with aqueous fluids, such as for example, water, or gastric juice.
- aqueous fluids such as for example, water, or gastric juice.
- I In tableting the material, I generally first prepare a granulation by stamping out slugs of the mixture of finely comminuted material with the starch, breaking up these slugs, and sifting them, returning the fines to the slug stamping machine and the particles coarser than the size desired for the granulation to the breaking machine.
- the material thus granulated is fed to tableting machines, and tableted as well known to the art.
- a wetting agent such as sodium lauryl sulfate or the like
- Example 2 Acetyl salicylic acid was milled 2 hours in a ball mill with .6% of silica aerogel. The average particle size of this preparation was 6 microns.
- Example 3 One of the tablets (I) the composition of which is described in the preceding example, was shaken thoroughly with 30 cc. ofwater. The solution was tested according to the Food and Drug Administration method, in comparison with one 30 cc. of water.v The shaking was continued until even the more slowly dissolving preparation II had given a substantially saturated solution. On
- the suspensions were filtered through Whatman filter paper #1, and the content of dissolved acetyl salicylic acid determined by titration.
- acetyl salicylic acid powder of a mean particle diameter of materially less than 14 microns was used in bulk as obtained directly from the comminution process, or whether said powder was compounded or compressed into tablets or the like, pure or comingled with excipients, or with agents such as starches, dextrose, or the like, which, by their swelling, promote the disintegration of the tablets upon immersion in water.
- osmotic cur- 7 1 patent (British, 25,486 (1912)), which is a mixture of acetyl salicylic acid with sodium bicarbonate, adapted to react chemically on contact with water to form readily soluble sodium acetyl salicylate. show that this compound has hardly any germicidal potency.
- composition of matter comprising acetyl salicylic acid having an average particle size substantially smaller than 14 microns.
- composition of matter comprising acetyl salicylic acid having an average particle size smaller than 9 microns.
- composition of matter comprising acetyl salicylic acid particles, a substantial proportion of which have a diameter smaller than 2 microns.
- composition Of matter comprising acetyl salicylic acid and an interspersing agent, and having an average particle size less than 9 microns.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Patented 18, 1942 2,293,350 ACETYL SALIOYLIC ACID PREPARATION Sven-e Quisling, Madison, Wis.
No Drawing. Application January 8 1941, Serial No. 373,011
. 4, Claims. (01. 10745) This invention is a continuation in part of my copending application Serial No. 260,109, filed March 16, 1939.
My invention relates to preparations of acetyl salicylic acid, having new and unpredictable physical, germicidal, and pharmacological properties. and having a particle size far smaller than has been known heretofore in preparations of acetyl salicylic acid.
Another object is to provide acetyl salicylic acid of increased therapeutic eilicacy.
Another object is to provide tablets, dusting powder, chewing gum, confections, or lozenges, containing acetyl salicylic acid in a state of increased availability to living organisms.
Another object is to provide tablets of acetyl salicylic acid, which will dissolve more rapidly and be more efficacious as an antiseptic or analgesic than products containing acetyl salicylic in like amount prior to this invention.
Further objects and applications of this invention will become apparent as the following detailed description proceeds.
In previous work conducted in 1933 and disclosed in part in my United States Patent 2,025,- 399, entitled Topical anaesthetics, I demonstrated the correlation between physical state, therapeuic availability and also germicidal action, particularly of hydroxy aromatic derivatives. This work, and further findings in part disclosed in my U. 8. Patent 2,152,917, and my U. S.-Patent 2,216,251, indicated that hydroxy aromatic derivatives influence the physical state of colloids, and give valuable unpredictable properties. This conclusion was confirmed and expanded in my copending application, Serial No. 260,109, flied.
' salicylic acid, because any attempt to precipitate this substance in colloidal state leads to decomposition into acetic and salicylic acids, the pharmacological actions both of which substantially differ from that of acetyl salicylic acid.
On comminuting acetyl salicylic acid by methods generally known and practiced by pharmaceutical manufacturers, coalescence of the par ticles, or "caking" occurs when the average particle size has been brought to the limit of an average particle diameter of 14 microns; the acetyl salicylic acid then forms a solid coating on the surfaces of the comminuting members and on other surfaces of the comminuting machine, thus rendering impossible further reduction of particle size.
Such preparations, from the viewpoint of this invention, are very coarse, and diiler profoundly from the preparations described below in their physical, pharmacological, and germicidal properties.
By a method not previously used in the field of pharmaceuticals, I have prepared comminuted acetyl salicylic acid, having an average diameter of the particles substantially less than 14 microns, preferably less than nine microns and in the order of two to eight microns, and even less than two microns.
These preparations have been found to differ from the previously known acetyl salicylic acid preparations in physical, colloid-chemical, pharmacological, and germicidal properties to a degree far in excess of what might have been expeeted merely from a consideration of the increased active surface area: and to posses unexpected and unpredictable properties, which could not have been anticipated even by those skilled in the art, prior to the actual preparation and investigation of these preparations.
I have found that by admixture of suitable anti-electrostatic and/or interspersing agents, the coalescence or caking of acetyl salicylic acidon grinding was prevented, so that the acetyl salicylic acid could be milled to any degree of comminution desired, and even to a substantially colloidal state. Suitable interspersing agents include any inorganic or organic substances, or combinations thereof, which are millable, whereby I mean those that are sumciently hard and brittle to be millable without caking in a mill. such as a ball mill, hammer mill, or the like, or which are otherwise available in an extremely fine state of comminution. Examples of substances usable as interspersing agents are for example almost allinorganic salts, or minerals, with a few exceptions readily discernible and obvious to those skilled in the art. These examples are primarily the highly hygroscopic salts, such as lithium bromide or silver fluoride, which may be used under anhydrous conditions, but are not desirable for practical purposes; the exceptionally soft salts, such as antimony chloride, which can not be readily milled because of their softness: and substances which are incompatible with acetyl salicylic acid, reacting with this acid to form unstable compounds, such as sodium carbonate, sodium bicarbonate, magnesium oxide, calcium oxide, or hydroxide, and the like. Numerous organic substances are suitable, particularly those having hard and brittle crystals, such as for example strychnin, tetrachlorphenolphthalein and gentian violet. Even of softer materials, a plurality were found, suitable if the comminution was carried out at a reduced temperature, such as for example the temperature of a mixture of acetone with solid carbon dioxide. Even of relatively soft organic materials, some may be used provided their particle size is initially very small: for example, lycopodium spores were found suitable as an interspersing agent.
The above discussion will enable those skilled in the art to select a great number of materials suitable for use as interspersing agents in comminuting acetyl salicylic acidi From the above disclosufe it is obvious that the materials in'question as interspersing agents are not confined to any one structural chemical group of substances, but maybe selected from chemically extremely heterogeneous materials. For this reason, and to facilitate the determina tion of adaptability of materials as interspersing agents, I have devised the following simple practical test to aid in the selection of interspersing agents:
Mix intimately 25 parts by volume (calculated from the specific gravity) of the substance to-be investigated for suitability as an interspersing agent, in a finely powdered state, with 85 parts by volume of acetyl salicylic acid. (Peculiarly, the specific gravity of acetyl salicylic acid had not previously been reported in the literature, but
"was found byme to be 1.392. The volume of the acetyl salicylic acid used for this determination was determined by immersing a weighed amount of the acid in a saturated solution of acetyl salicylic acid in benzene, and observing the increase in volume.) Charge the mixture into a ball mill, charged with pebbles of approximately one-half inch average diameter, using a number of pebbles having an apparent volume about equal to that of the charge, including in this apparent volume the space between the pebbles, and mill at a rate of about '10 revolutions of the mill jar per minute.
Under these conditions, pure acetyl salicylic acid, without any interspersing agent, was found to attain average particle sizeof 14 microns in twenty minutes, but would cake immediately thereafter. Any prolongation of the caking time beyond twenty minutes, or to an average Particle size less than 14 microns, showed at least some suitability as an interspersing agent for the purposes of this invention, for the material tested. For practical purposes, it was found the material should preferably delay caking at least additional minutes, but with the preferred interspersing agents and conditions, as further detailed below, no caking took place even when the milling was continued for several days, or even indefinitely.
In this specification, and in the claims, I understand the term interspersing agent" to mean a substance, which under the test conditions described above will delay the caking of acetyl salicylic acid substantially beyond the time reouired to comminute it to an average particle ing agents, to avoid substances likely not to give good results, and the above testing procedure will merely serve as a supplemental aid in the selection, and for definition of substances suitable as interspersing agents.
Among "the numerous interspersing agents found suitable, may be mentioned particularly tri-calcium phosphate, and silica aerogel, prepared as disclosed in the U. S. P. 2,093,454, issued September 21, 1937, to S. S. Kistler. It was found that the admixture of only .2% to .9% of either of these substances, and/or 1% to 2% boric acid fully prevented caking of acetyl salicylic acid, even on milling in. a pebble mill for eight hours or more, or to an average particle size of 2 microns, or less. The finest particle sizes were generally attained using slightly larger amounts, say
2% of the said interspersing agents. Kaolin was also very suitable, but should preferably be used in amounts of about 7 to 15% by weight. Other suitable interspersing agents were inorganic solids substantially chemically inert to acetyl salicylic acid, such as kaolin, magnesium silicate, carbon, sulphur, calcium phosphates, ferric acetate, boric acid, silver chloride, lead sulphate, barium sulphate, lead bichromate, copper sulfide, mercuric ammonium chloride, aluminum powder and the like. Among organic substances, the suitable materials were found among those having a relatively high degree of hardness and brittleness, at the temperature of the comminution process, or otherwise available in an unusually fine degree of comminution, such as for example strychnin,
ephetirin sulphate, galuteolin, lycopodium spores, and the hard black resinous composite materials remaining in the still upon distilling off all material as volatile at 300 degrees C. in 1 mm. vacuum from a petroleum pitch, and the like.
From the vast number of suitable interspersing agents clearly indicated by the above-enumeration of numerous suitable substances of different chemical origin and character, it is obviously easy to select several which have pharmacological or germicidal properties adapted for the particular applications in view, or which are therapeutically inert.
While most of the materials enumerated above by way of example, and not of limitation, were substantially insoluble in water, I may also use water soluble and even hygroscopic substances, provided that the comminution process is carried out under practically anhydrous conditions.
Of most of the above substances, 5 to 25% by volume was required to prevent caklng, the most suitable amount of any one interspersing agent being easy to determine by experiment, in a manner obvious to those skilled in the art.
The following example may serve to further illustrate the invention:
Example 1 99.7 parts by weight of crystalline acetyl salicylic acid were thoroughly intermixed with .3 part by weight of finely powdered tri-calcium phosphate, and milled in a ball mill with pebbles, at 70 revolutions per minute. After four hours the milling was interrupted, and the comminuted product removed. It was found to have an average particle size of 6 microns. The apparent specific gravity was .682, or approximately lower than the apparent specific gravities of the finest powdered acetyl salicylic acid preparations hitherto available. The preparations contemplated in this invention, unless subjected to compression or like treatments, subsequently to their preparation, have apparent specific gravities below .880, while the most finely comminuted acetyl salicylic acid preparations known heretofore have apparent specific gravities appreciably higher than .880, The preparation offered very little resistance to solid objects; even a relatively light object such as a piece of wood fell through even a foot deep layer of the milled product, while of course such a piece of light material would not at all sink through the finest acetyl salicylic acid previously known. The product of this invention behaved almost like a liquid, or like colloidal carbon: it flowed when handled in a glass container, always forming a substantially horizontal surface, and, on agitation with a glass rod or a pencil. it offered hardly any percepticle resistance. Viewed under the microscope; in the dark field of a cardioid condenser, suspended in a non-solvent liquid medium such as a concentrated solution of acetyl salicylicacid in an oil, or in perchlorethylene, it showed a large number of extremely minute particles, smaller than .1 micron, and having vivid Brownian motion.
In an attempt to separate the interspersing mediate between the specific gravity of the aectyl salicylic acid and of the interspersing agent. The same was true if the material was compressed to form a tablet, and this tablet was then brokenup and dispersed in the liquid.
While I do not wish to confine myself to any theoretical views, it would appear, from the above findings, that the product resulting upon comminution of acetyl salicylic acid with an interspersing agent is not merely a mechanical-mixture, but manifestly consists of electrochemically the particles of acetyl salicylic acid will repel agent, and thus to obtain pureacetyl salicylic acid, I intermixed some of the product of the above experiment with a large excess of perchlorethylene. If a mixture of tri-calcium phosphate, and ordinary finely powdered acetyl salicylic acid, having an average particle size of 14 mi-' crons, or larger, were intermixed with perchlorethylene, the acetyl salicylic acid would float up to the surface of the liquid, and the tri-calcium phosphate, having a higher specific gravity, would sink to the bottom. The same was true of a mixture of the most finely ground acetyl salicylic acid heretofore available in commerce,
.or'otherwise, with sodium bicarbonate, as disclosed in the British Patent, No. 25,486 (1912), to Sefton-Jones. However, unexpectedly and surprisingly, it was found that when the product of the above Example 1 was intermixed with perohlorethylene, all ofthe solid material would float, and no separation took place.
To confirm this finding, another experiment was made, grinding acetyl salicylic acid for two hours with 15% of its weight of kaolin. The average particle size was found to besix microns, This composition again was intermixed witha large excess of perchlorcthylene. Again all of the solid material 'fioated to the surface of the liquid, and no separation took place, although if the ingredients were intermixed. prior to the milling step, they would readily separate in two layers, the acetyl salicylic acid floating to the surface and the kaolin sinking to the bottom of the container.
To further investigate this observation, using ingredients having a greater difference in specific gravity, and thus presumably easier to separate, acetyl salicylic acid was milled as before,
one hour, with twice its weight of lead sulfate as the interspersing agent. The resulting mixture, having an average particle size of 9 microns, was intermixed with an excess of perchlorethylene. Again no separation took place, and all of the solid material sank to the bottom of the container, although prior to the milling step, the ingredients were readily separable.
The experiment was repeated using numerous additional interspersing agents, and in all the proportions tried, the resultant product'could other particles of acetyl salicylic acid, having the. same electrical charge, and will attract the particles of the interspersing agent, which have electrical charges different from those of the particles of acetyl salicylic acid. If this theory is correct, it may be expected that a substance having exactly the, same dielectric constant as acetyl salicylic acid would not be effective as an interspersing agent, even though brittle and millable in itself; but this appears a purely theoretical consideration. I find it much more practical to'deflne the substances suitable as interspersing agents for the process by the simple extremely finely comminuted acetyl salicylic acid from the interspersing agent by a simple gravity procedure as described above, I succeeded in bringing about this separation by preparing an interspersing agent soluble in a substance which is substantially a non-solvent for acetyl salicylic acid, and by then dissolving out the interspersing agent from the product obtained by milling.
For this purpose I dissolved a hard and brittle resinous pitch known to the trade as "Burgundy pitch" in perchlorethylene. and filtered the solution to remove all traces of material insoluble in perchlorethylene. I then distilled off the solvent on an oil bath, and finally removed all traces of the solvent by heating on an oil bath to a temperature of 250 degrees C., in a vacuum of 1 mm.
The resin thus purified was very brittle, and was completely soluble in perchlorethylene.
This resin was comminuted as finely as possible with mortar and pestle, and was then intermixed with twice its weight of acetyl salicylic acid, and the mixture was placed in a pebble mill. The mill jar was immersed in a cooling bath consisting of acetone saturated with solid carbon dioxide. Additional solid carbon dioxide was added from time to time, so that some undissolved carbon dioxide was present throughout the experiment in sufilcient amounts to maintain a uniform very low temperature, but not in such quantities as to interfere with the operation of the pebble mill. The mill was not started until after an hour of cooling to allow time for uniform temperature throughout the charge.
The mill was then operated two hours. The resultant powder had an average particle size of 6 microns. This powder was intermixed with an excess of perchlorethylene, which dissolved the resin, but did not dissolve acetyl salicylic acid to any appreciable extent, particularly if the perchlorethylene had been kept in contact with acetyl salicylic acid prior to its use in this process. The acetyl salicylic acid was separated from the resin solution by centrifugation, and was washed from traces of the resin containing solution by repeated suspension in benzene, and centrifugation. It was freed from excess liquid by centrifugation and rapid drying. The resultant acetyl salicylic acid had an average particle size of six microns, and wasfree from the interspersing agent. By classification, it was possible to separate this preparation in fractions of different fineness. This could be done, for example, by allowing a vertical air current to pass upwardly through the preparation, and by collecting the particles carried upward on a dust filter made of cotton in the upper part of the tube, in manner obvious cardioid condenser, to have a particle size well below one micron.
In preparing the acetyl salicylic acid of this "invention free from the interspersing agents, it
was found important to remove as thoroughly as possiblethe liquid medium in which the separation had been effected, prior to drying the preparation. Even though the solubility of acetyl salicylic acid in perchlorethylene, or in benzol, was but slight, the vaporation of relatively large quantities of this liquid in immediate contact with the acetyl salicylic acid resulted in the deposit of acetyl salicylic acid in sufflcient amounts to cause adhesion between theparticles. However, if the liquid was drained off rapidly, substantially without evaporation on a centrifuge filter, in manner obvious to those skilled in the art, then the particles remained separated even on drying, and any adhesion between them was so slight as to be readily broken up even by moderate agitation, or vibration.
The acetyl salicylic acid prepared directly by milling with an interspersing agent obviously can be separated into fractions of different particle size by the methods already outlined. Industrially, the most practical method is that of separation of the finer particles by air current, in a cyclon" type separated, well known in the art. In this manner preparations having an average particle size as low as .1 micron, and less, were found to be obtainable.
,While in the above example reference has been made to Burgundy pitch" as an interspersing agent and to perchlorethylene as a solvent therefore, itis apparent that any interspersing agent which is soluble in a liquid non-solvent for acetyl salicylic acid may be used instead of "Burgundy pitch." ,For example,- Egyptian asphalt and a turpentine resin known to the trade as Petrex" and produced by the Hercules Powder Company est melting grades of these products being preferable. Instead of perchlorethylene, any other liquid which is substantially a nonsolvent for acetyl salicylic acid, and a solvent for the interspersing agent employed, is suitable, such as for example benzene and carbon-tetrachloride.\ Thus, using as interspersing agent a mixture of equal parts of Petrex" and Santo resin" with three times their combined weight of acetyl salicylic acid, the comminution was carried out sucessfully in a ball mill at room temperature, and both carbon-tetrachloride and benzene, respectively. were used to separate the interspersing agent from the acetyl salicylic acid.
The pure finely comminuted acetyl salicylic acid preparations thus prepared obviously may be compounded with other ingredients used in medicine, and may be compressed into tablets.
However, for practical applications, I prefer to employ preparations in which the intersecting agent remains present. The number of suitable interspersing agents is so great, and their properties so varied, that it is easy to find one suitable for almost any requirement. For example, a composition comprising less than 5% of a therapeutically inert interspersing. agent, such as kaolin, or say .2% to 3% of tricalcium phosphate, and/or silica aerogel can be used freely in therapeutical compositions, the amount of these interspersing agents present being therapeutically negligible.
The finely comminuted acetyl salicylic acid preparations described above are eminently adapted for use as dusting powders for example for local treatment to infiammations of mucous membranes of the human body. The extreme ease of distribution of this powder by blowing or spraying, as well as the surprising antiseptic properties described below render them far superior to acetyl salicylic acid preparations previously available for these purposes, and particularly superior to the preparation contemplated in the British patent to Sefton-Jones, 25,486 (1912), which is chemically unstable and practically devoid of antiseptic properties, as will be described later in this specification.
The preparations of pure acetyl salicylic acid of an average particle size substantially below 14 microns, as well as the preparations in which the interspersing agents are present, are for most purposes conveniently used in the form of tablets. To facilitate the disintegration of such' tablets, the preparations are intermixed with a tablet disintegrating agent having the property of swelling, so as to break up the tablets when in contact with aqueous fluids, such as for example, water, or gastric juice. To secure the full advantage of the high speed of dissolution of the preparations of this invention, I prefer to use a somewhat higher percentage of the tablet disintegrating agent preferably starch, than is usual; for example I find 25% by'weight of unswollen corn starch to be a suitable amount. In tableting the material, I generally first prepare a granulation by stamping out slugs of the mixture of finely comminuted material with the starch, breaking up these slugs, and sifting them, returning the fines to the slug stamping machine and the particles coarser than the size desired for the granulation to the breaking machine. The material thus granulated is fed to tableting machines, and tableted as well known to the art.
In some cases, particularly when the desired product is made up in tablet form in a tabletforming machine or the like, I found it advansalicylic acid previously known.
tageous to include as an ingredient in the preparation a wetting agent, such as sodium lauryl sulfate or the like, for example, in the amount tive humidity has been higher, to keep the tablets, or the acetyl salicylic acid preparation in thin layers in contact with dry air, until their moisture content is lower than that corresponding to an equilibrium with air of a relative humidity of 45%. I have found that the acetyl salicylic acid products made with stable, substantially inert interspersing agents, when prepared at a relative humidity below 45%, are at least as stable as any acetyl salicylic acid preparation previously available, and that they conform with the requirements of the U. S. Pharmacopoea in regard to salicylic acid content even after more than a year of storage, but that 1 if the manufacturing processes have been carried out at a relative humidity higher than 45%, without a subsequent drying operation, then the product will be less stable, probably due to some absorption eiiect peculiar to these highly surface active preparations. The stability is particularly favorable in those preparations which contain less than 5% of the interspersing agent, such as preparations made with .2% to 5% of silica aerogel or of tricalcium phosphate asinterspersform soluble salts. Such preparations of prior art (for example the mixture of flnely pulverized acetyl. salicylic acid with sodium bicarbonate disclosed in the British Patent 25,486 (1912) to Sefton-Jones, or with magnesium oxide as disclosed in the Dutch Patent 12,268 to- Wuliing) even when stored under cool and dry conditions, are unstable and will decompose to the extent of at least several per cent monthly.
The preparations of this invention are far more rapidly soluble 'than any preparations of acetyl This is illustrated in the followingexperiments:
Example 2 Acetyl salicylic acid was milled 2 hours in a ball mill with .6% of silica aerogel. The average particle size of this preparation was 6 microns.
-- The product was granulated with of corn starch and tableted to give tablets containing ,5 grains each of acetyl salicyclic acid. In the following tabulations these tablets are referred to p grate in 250 cc..of water at 25 degrees C., then titration theamount of acetyl salicylic acid in true solution, (not merely dispersion).
Amount of acetyl salicylic acid dissolved, in
per cent I Number of tablets in 260 cc. water Percent Pa 0 t 'lablcts I 74. 9 r 57 i?! Tablets ii 28.1 26 25. 1
This test shows a much faster solution of the acetyl salicylic acid preparation of this in,- vention, under conditions of dissolution resembling those of preparing a gargle'. For these purposes, it is seen that the preparation of this invention gives a solution more than twice as concentrated, and correspondingly more efiicient, therapeutically, than a preparation containing an identical quantity of acetyl salicylic acid comminuted to the finest degree known heretofore.
A comparison between the germicidal potency of the preparations I and II resulted in the unexpected discovery of a germicidal potency of ,the preparations of this invention far exceeding what might have been anticipated even in view of the increase of solubility produced. This is illustrated by the following example:
Example 3 One of the tablets (I) the composition of which is described in the preceding example, was shaken thoroughly with 30 cc. ofwater. The solution was tested according to the Food and Drug Administration method, in comparison with one 30 cc. of water.v The shaking was continued until even the more slowly dissolving preparation II had given a substantially saturated solution. On
filtration, and subsequent analysis, from the clear.
filtrate, it was found that the concentration of truly dissolved acetyl salicylic acid was the same for all three preparations, within a limit of 5%, and that therefore the differences found in germicidal potency cannot be ascribed merely to differences in concentration of the client.
It was found that under the conditions of the test (Food and Drug Administration method) the suspension of the tablet (I) killed of the test organisms (Staphylococcus aureus, 24 hour culture) within 3 minutes, but not within 2 minutes; that the suspension of the tablet (II) killed the same test organisms in 15 minutes, but not in 10 minutes; and that the tablet (III) did not kill the same test organisms even on continued exposure for minutes.
To compare the germicidal potency of acetyl salicylic acid, preparedaccording to my invention, using 1% of silica aerogel as an interspersing agent, having an average particle diameter of from 4 to 6 microns, with acetyl saliactive ingrecylic acid of the finest average particle diameter heretofore available, found to be 14 microns, tests were made using bacillus colt (Escherichia coli) and Staphylococcus aureus as'test organisms. The former organism commonly causes infections or the intestinal tract, kidney, and bladder; the latter of the nose. throat, and skin. Several types of tests were made with conforming results. In one test and 20% of acetyl salicylic acid powder, having-an average particle diameter of from 4 to 6 microns. prepared as stated above in Example 2, was suspended in water by shaking. One cc. of a water suspension of B. colt was then intermixed with 5 cc. of the suspension. From a platecount it was determined that 2,080,000 bacteria were present in each cc. of inoculum. At intervals of 30 seconds, 1 minute, 3 minutes, 5 minutes, minutes, minutes, and 1 hour, one loop full of the mixture was inoculated into tubes of sterile beef peptone broth at pH 7.0. The cultures were incubated at 37 degrees C. and were examined at 12 hour intervals for growth, as indicated by a distinct and heavy cloudiness of the medium.
It was found that preparations of acetyl salicylic acid having an average particle diameter of 4 to 6 microns, made according to the method described above, killed 100% of the test organisms within 5 minutes, under the conditions stated above in contradistinction to the preparations of commercially available acetyl salicylic acid,
having an average particle diameter of 14 to 26 microns, which did not completely kill the test organisms even after 20 to 30 minutes. To determinewhether the difference might not have been due to differences in the rates of dissolution, the suspensions were filtered through Whatman filter paper #1, and the content of dissolved acetyl salicylic acid determined by titration. The difference in concentration was found to be less than 5%, and entirely insufilcient to explain the very great difference in germicidal p v- These germicidal properties were equally pro-' nounced whether acetyl salicylic acid powder of a mean particle diameter of materially less than 14 microns was used in bulk as obtained directly from the comminution process, or whether said powder was compounded or compressed into tablets or the like, pure or comingled with excipients, or with agents such as starches, dextrose, or the like, which, by their swelling, promote the disintegration of the tablets upon immersion in water. Without wishing to commit myself to any theory regarding the cause of this surprising and unpredictable enhancement of germicidal action, I believe that bacteria are attracted electrostatically to colloidal particles of acetyl salicylic acid present in the preparations of this invention, and that they are thus brought in intimate contact with pauci-molecular layers of highly supersaturated acetyl salicylic acid solution surround-'- ing such colloidal particles. The presence of such peculiar forces of surface attraction is at least strongly indicated by the fact that it proved impossible to effect separation of the interspersing agent from the acetyl salicylic acid of my preparations, by gravity separation means, as fully discussed above. It is also probable that a sharp concentration gradient exists in the immediate proximity of such colloidal particles, so that the diflerent parts of a bacterium contacting such a colloidal particle will be in contact with solutions of different concentration, whereby osmotic cur- 7 1 patent (British, 25,486 (1912)), which is a mixture of acetyl salicylic acid with sodium bicarbonate, adapted to react chemically on contact with water to form readily soluble sodium acetyl salicylate. show that this compound has hardly any germicidal potency. Similar tests with mixtures of acetyl salicylic acid and magnesia and calcium oxide, hydroxide or carbonate, confirm that the salts of acetyl salicylic acid formed on dissolution in water of such compounds are germicidally very much less potent than the free acid, in spite of their higher solubility. This is another practically important distinction between the product of this invention, and that of the Berton-Jones patent.
The average particle sizes of the preparations disclosed in this specification, except where otherwise expressly stated, were determined by the method described by E. L. Gooden and Charles M.
Smith, in Industrial and Engineering Chemistry, pages 479 to 482, August, 1940, with suggested modifications supplied by these authors for use in connection with the study of powders of extremely fine particle size. The references made in the claims to preparations of certain average particle sizes, have in view values obtained by this method.
Pharmacologically, I have observed that the comparative rate of therapeutic activity of preparations made by my process of acetyl salicylic acid is distinctly shorter and more intense than when similar dosages of preparations made by manufacturers now selling similar products are employed. However, the therapeutic action of drugs on human beings is difllcult to measure accurately and, although I have compared the results using my preparations with others on the market, on a number of patients for the indicated therapeutic applicability of this product with results that seem to greatly favor my preparation, I have preferred to characterize and define the preparations of the present invention particularly in terms of physical and chemical I properties more objectively determinable.
It is understood that the invention has many pharmaceutical applications and that procedures and ingredients referred to in the application are for the purpose of illustration only and not to limit the scope of the claims, in which it is intended to claim all novelty inherent in this invention as broadly as possible, in view of prior art.
I claim:
1. A composition of matter comprising acetyl salicylic acid having an average particle size substantially smaller than 14 microns.
2. A composition of matter comprising acetyl salicylic acid having an average particle size smaller than 9 microns.
3. A composition of matter comprising acetyl salicylic acid particles, a substantial proportion of which have a diameter smaller than 2 microns.
4. A composition Of matter comprising acetyl salicylic acid and an interspersing agent, and having an average particle size less than 9 microns.
SVERRE QUISLING.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US373611A US2293359A (en) | 1941-01-08 | 1941-01-08 | Acetyl salicylic acid preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US373611A US2293359A (en) | 1941-01-08 | 1941-01-08 | Acetyl salicylic acid preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2293359A true US2293359A (en) | 1942-08-18 |
Family
ID=23473124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US373611A Expired - Lifetime US2293359A (en) | 1941-01-08 | 1941-01-08 | Acetyl salicylic acid preparation |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2293359A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2438106A (en) * | 1944-06-09 | 1948-03-23 | Wyeth Corp | Peroral penicillin compositions |
| US2538092A (en) * | 1949-03-04 | 1951-01-16 | Merck & Co Inc | Water-soluble sulfaquinoxaline tablet |
| US2581035A (en) * | 1949-03-26 | 1952-01-01 | Nat Drug Co | Anion exchange resin antacid |
| DE938566C (en) * | 1953-02-22 | 1956-02-02 | Hans Koehler | Process for the production of storable and disintegratable pharmaceutical tablets |
| DE960922C (en) * | 1952-07-24 | 1957-03-28 | Fritz Neuwald Dr | Process for the production of stable mixtures of inherently incompatible drugs |
| DE1012432B (en) * | 1954-07-29 | 1957-07-18 | Josef Ellendorf & Co Dr Med | Process for the production of durable, phenol-containing molded preparations for the internal treatment of skin diseases, especially psoriasis |
| US4639368A (en) * | 1984-08-23 | 1987-01-27 | Farmacon Research Corporation | Chewing gum containing a medicament and taste maskers |
| US20070224312A1 (en) * | 2006-02-21 | 2007-09-27 | Cadbury Adams Usa Llc. | Sealed package for multiple products |
| EP2429502A4 (en) * | 2009-05-11 | 2012-10-24 | Bayer Healthcare Llc | METHOD AND COMPOSITIONS FOR IMPROVING THE ADMINISTRATION OF MEDICINAL PRODUCTS |
| US20190105267A1 (en) * | 2013-04-30 | 2019-04-11 | Otitopic Inc. | Dry powder formulations and methods of use |
| US11857684B2 (en) | 2020-11-13 | 2024-01-02 | Bayer Healthcare Llc | Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof |
-
1941
- 1941-01-08 US US373611A patent/US2293359A/en not_active Expired - Lifetime
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2438106A (en) * | 1944-06-09 | 1948-03-23 | Wyeth Corp | Peroral penicillin compositions |
| US2538092A (en) * | 1949-03-04 | 1951-01-16 | Merck & Co Inc | Water-soluble sulfaquinoxaline tablet |
| US2581035A (en) * | 1949-03-26 | 1952-01-01 | Nat Drug Co | Anion exchange resin antacid |
| DE960922C (en) * | 1952-07-24 | 1957-03-28 | Fritz Neuwald Dr | Process for the production of stable mixtures of inherently incompatible drugs |
| DE938566C (en) * | 1953-02-22 | 1956-02-02 | Hans Koehler | Process for the production of storable and disintegratable pharmaceutical tablets |
| DE1012432B (en) * | 1954-07-29 | 1957-07-18 | Josef Ellendorf & Co Dr Med | Process for the production of durable, phenol-containing molded preparations for the internal treatment of skin diseases, especially psoriasis |
| US4639368A (en) * | 1984-08-23 | 1987-01-27 | Farmacon Research Corporation | Chewing gum containing a medicament and taste maskers |
| US20070224312A1 (en) * | 2006-02-21 | 2007-09-27 | Cadbury Adams Usa Llc. | Sealed package for multiple products |
| EP2429502A4 (en) * | 2009-05-11 | 2012-10-24 | Bayer Healthcare Llc | METHOD AND COMPOSITIONS FOR IMPROVING THE ADMINISTRATION OF MEDICINAL PRODUCTS |
| US11135188B2 (en) | 2009-05-11 | 2021-10-05 | Bayer Healthcare Llc | Method and composition to improve absorption of therapeutic agents |
| US20190105267A1 (en) * | 2013-04-30 | 2019-04-11 | Otitopic Inc. | Dry powder formulations and methods of use |
| US11819569B2 (en) | 2013-04-30 | 2023-11-21 | Vectura Inc. | Treating inflammation with inhaled aspirin |
| US11865210B2 (en) * | 2013-04-30 | 2024-01-09 | Vectura Inc. | Dry powder formulations and methods of use |
| US11857684B2 (en) | 2020-11-13 | 2024-01-02 | Bayer Healthcare Llc | Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof |
| US12296051B2 (en) | 2020-11-13 | 2025-05-13 | Bayer Healthcare Llc | Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2293359A (en) | Acetyl salicylic acid preparation | |
| JP5216177B2 (en) | Method for inhibiting microorganisms in aqueous systems | |
| DE69222950T2 (en) | PELLEL-SOLUBLE ORAL ADMINISIBLE MEDICINAL PRODUCTS CONTAINING ACID LABEL COMPOUNDS | |
| DE69123123T2 (en) | A physical form of N- [4- [5- (cyclopentyloxycarbonylamino) -1-methyl-indol-3-ylmethyl] -3-methoxybenzoyl] -2-methylbenzenesulfonamide, a process for its preparation and pharmaceutical compositions containing it | |
| DE3855037T2 (en) | Granular calcium hypochlorite mixture and method of manufacture | |
| EP0122219A2 (en) | Substituted carboxylic-acid resins, process for their manafacture, use thereof and pharmaceutical compositions containing these resins | |
| JPS62265295A (en) | Spray drying lactose product and its production | |
| EP0275468A1 (en) | Pharmaceutical compositions containing clodronate, and process for their preparation | |
| EP0168526B1 (en) | Enzyme preparation for use in powder detergents | |
| JPS63270687A (en) | Potassium clavulanate | |
| WO2003039513A1 (en) | Method for the formation of ibuprofen crystals | |
| DE602004006507T2 (en) | amoxicillin trihydrate | |
| US4950653A (en) | Solid iodophor composition | |
| DE69910188T2 (en) | MEDICINE CONTAINING CARVEDILOL | |
| EP0417588B1 (en) | Process for the preparation of a complexed drug | |
| DE2734622A1 (en) | PROCESS FOR THE PRODUCTION OF SOLID SODIUM AMOXYCILLIN | |
| JPS6181753A (en) | Non-dusting anti-coccidium premix composition and its production | |
| GB2180748A (en) | Stable aqueous suspensions | |
| US3293126A (en) | Water-dispersible lignosulfonate formulations of metal ethylene bis-dithiocarbamates | |
| US2555463A (en) | Stabilized sodium pantothenate composition | |
| DE69005993T2 (en) | Process for the production of a ranitidine resin absorbate. | |
| US2791530A (en) | Stabilized fumagillin compositions | |
| US4458070A (en) | Process for the manufacture of crystalline sodium cefoperazone | |
| US2188944A (en) | Tableted polychlorophenol salts | |
| DE1944693A1 (en) | Drug preparation |